Ahmad A. Cluntun

Ahmad A. Cluntun

Auto-generated profile, based on publicly available information

Ahmad A. Cluntun

Department of Biochemistry, University of Utah, Salt Lake City, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Trends in Cancer
Verified
Journal Article
Closed access
ACAhmad A. Cluntun
Ahmad A. Cluntun
MLMichael J Lukey
Michael J Lukey
RCRichard A. Cerione
Richard A. Cerione
JLJason W. Locasale
Jason W. Locasale

9 July 2014 in eLife
Verified
Journal Article
Open access
ASAlexander A Shestov
Alexander A Shestov
XLXiaojing Liu
Xiaojing Liu
ZSZheng Ser
Zheng Ser
ACAhmad A Cluntun
Ahmad A Cluntun
YHYin P. Hung
Yin P. Hung
JLJason W Locasale
Jason W Locasale
Aerobic glycolysis or the Warburg Effect (WE) is characterized by the increased metabolism of glucose to lactate. It remains unknown what quantitative changes to the activity of metabolism are necessary and sufficient for this phenotype. We developed a computational model of glycolysis and an integrated analysis using metabolic control analysis (MCA), metabolomics data, and statistical simulations. We identified and confirmed a novel mode of regulation specific to aerobic glycolysis where flux through GAPDH, the enzyme separating lower and upper glycolysis, is the rate-limiting step in the pathway and the levels of fructose (1,6) bisphosphate (FBP), are predictive of the rate and control points in glycolysis. Strikingly, negative flux control was found and confirmed for several steps thought to be rate-limiting in glycolysis. Together, these findings enumerate the biochemical determinants of the WE and suggest strategies for identifying the contexts in which agents that target glycolysis might be most effective.

10 March 2023 in Science
Verified
Journal Article
Closed access
KHKevin G. Hicks
Kevin G. Hicks
ACAhmad A. Cluntun
Ahmad A. Cluntun
HSHeidi L. Schubert
Heidi L. Schubert
SHSean R. Hackett
Sean R. Hackett
JBJordan A. Berg
Jordan A. Berg
JRJared Rutter
Jared Rutter
Metabolic networks are interconnected and influence diverse cellular processes. The protein-metabolite interactions that mediate these networks are frequently low affinity and challenging to systematically discover. We developed mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically (MIDAS) to identify such interactions. Analysis of 33 enzymes from human carbohydrate metabolism identified 830 protein-metabolite interactions, including known regulators, substrates, and products as well as previously unreported interactions. We functionally validated a subset of interactions, including the isoform-specific inhibition of lactate dehydrogenase by long-chain acyl–coenzyme A. Cell treatment with fatty acids caused a loss of pyruvate-lactate interconversion dependent on lactate dehydrogenase isoform expression. These protein-metabolite interactions may contribute to the dynamic, tissue-specific metabolic flexibility that enables growth and survival in an ever-changing nutrient environment.

1 February 2020 in Cell Metabolism
Verified
Journal Article
Closed access
CBClaire L. Bensard
Claire L. Bensard
DWDona R. Wisidagama
Dona R. Wisidagama
KOKristofor A. Olson
Kristofor A. Olson
JBJordan A. Berg
Jordan A. Berg
NKNathan M. Krah
Nathan M. Krah
JRJared Rutter
Jared Rutter

23 September 2015 in Cancer & Metabolism
Verified
Journal Article
Open access
PDF file
ACAhmad A. Cluntun
Ahmad A. Cluntun
HHHe Huang
He Huang
LDLunzhi Dai
Lunzhi Dai
XLXiaojing Liu
Xiaojing Liu
YZYingming Zhao
Yingming Zhao
JLJason W. Locasale
Jason W. Locasale
Glucose metabolism links metabolic status to protein acetylation. However, it remains poorly understood to what extent do features of glucose metabolism contribute to protein acetylation and whether the process can be dynamically and quantitatively regulated by differing rates of glycolysis. Here, we show that titratable rates of glycolysis with corresponding changes in the levels of glycolytic intermediates result in a graded remodeling of a bulk of the metabolome and resulted in gradual changes in total histone acetylation levels. Dynamic histone acetylation levels were found and most strongly correlated with acetyl coenzyme A (ac-CoA) levels and inversely associated with the ratio of ac-CoA to free CoA. A multiplexed stable isotopic labeling by amino acids in cell culture (SILAC)-based proteomics approach revealed that the levels of half of identified histone acetylation sites as well as other lysine acylation modifications are tuned by the rate of glycolysis demonstrating that glycolytic rate affects specific acylation sites. We demonstrate that histone acylation is directly sensed by glucose flux in a titratable, dose-dependent manner that is modulated by glycolytic flux and that a possible function of the Warburg Effect, a metabolic state observed in cancers with enhanced glucose metabolism, is to confer specific signaling effects on cells.

1 October 2019 in Cell Reports
Verified
Journal Article
Open access
MLMichael J Lukey
Michael J Lukey
ACAhmad A. Cluntun
Ahmad A. Cluntun
WKWilliam P. Katt
William P. Katt
MLMiao-Chong J. Lin
Miao-Chong J. Lin
JDJoseph E. Druso
Joseph E. Druso
RCRichard Cerione
Richard Cerione
Efforts to target glutamine metabolism for cancer therapy have focused on the glutaminase isozyme GLS. The importance of the other isozyme, GLS2, in cancer has remained unclear, and it has been described as a tumor suppressor in some contexts. Here, we report that GLS2 is upregulated and essential in luminal-subtype breast tumors, which account for >70% of breast cancer incidence. We show that GLS2 expression is elevated by GATA3 in luminal-subtype cells but suppressed by promoter methylation in basal-subtype cells. Although luminal breast cancers resist GLS-selective inhibitors, we find that they can be targeted with a dual-GLS/GLS2 inhibitor. These results establish a critical role for GLS2 in mammary tumorigenesis and advance our understanding of how to target glutamine metabolism in cancer.